| Literature DB >> 32550021 |
Viviane Castello-Simões1, Marlus Karsten1,2, Vinicius Minatel1, Rodrigo Polaquini Simões1, Ester Silva1, Nayara Yamada Tamburús1, Ross Arena3, Audrey Borghi-Silva1, Aparecida Maria Catai1.
Abstract
INTRODUCTION: Expiratory flow limitation (EFL) during moderate intensity exercise is present in patients with myocardial infarction (MI), whereas in healthy subjects it occurs only at a high intensity. However, it is unclear whether this limitation already manifests in those with stable coronary artery disease (CAD) (without MI).Entities:
Year: 2020 PMID: 32550021 PMCID: PMC7260653 DOI: 10.1155/2020/4629548
Source DB: PubMed Journal: Cardiol Res Pract ISSN: 2090-0597 Impact factor: 1.866
Figure 1Flowchart showing subjects' participation in the study. n, number of individuals; BMI, body mass index; RMI, recent myocardial infarction group; LMI, late myocardial infarction group; CAD, stable coronary artery disease group; CG, control group.
Age, anthropometry, risk factors, and medications of all groups.
| RMI ( | LMI ( | CAD ( | CG ( | |
|---|---|---|---|---|
| Age, years | 50.9 ± 5.5 | 54.7 ± 6.7 | 58.0 ± 4.4 | 51.8 ± 7.9 |
| Anthropometry | ||||
| Height, m | 1.68 ± 0.06 | 1.70 ± 0.08 | 1.69 ± 0.06 | 1.72 ± 0.05 |
| Weight, kg | 78.6 ± 10.2 | 83.4 ± 15.0 | 78.8 ± 10.0 | 76.5 ± 7.0 |
| Body mass index, kg/m2 | 28.0 ± 4.3 | 28.7 ± 4.5 | 27.5 ± 2.3 | 26.0 ± 2.5 |
| Risk factors, | ||||
| Past of smoking | 1 (12.5) | 8 (67) | 4 (44) | 1 (8) |
| Hypertension | 3 (37.5) | 8 (67) | 4 (44) | 0 |
| Dyslipidemia | 7 (87.5) | 10 (83) | 8 (89) | 3 (25) |
| Diabetes | 3 (37.5) | 5 (42) | 2 (22) | 0 |
| Family history of CD | 8 (100) | 9 (75) | 9 (100) | 10 (83) |
| Medications, | ||||
| Beta-blockers | 6 (75) | 9 (75) | 3 (33) | 0 |
| ACE inhibitor | 3 (37.5) | 8 (67) | 2 (22) | 0 |
| Diuretic | 3 (37.5) | 5 (42) | 0 | 0 |
| Hypoglycemic | 3 (37.5) | 5 (42) | 2 (22) | 0 |
| Lipid lowering | 7 (87.5) | 10 (83) | 8 (89) | 3 (25) |
| Antiplatelet/anticoagulant | 8 (100) | 12 (100) | 6 (67) | 0 |
Data are presented as mean ± SD or absolute value (percentage) of occurrence. RMI, recent myocardial infarction group; LMI, late myocardial infarction group; CAD, stable coronary artery disease group; CG, control group; n, number of individuals; CD, coronary disease; ACE, angiotensin-converting enzyme. Significant difference in relation to CG. +Significant difference in relation to RMI (p < 0.05). The chi-square test was used.
Clinical data of groups with coronary artery disease.
| RMI ( | LMI ( | CAD ( | |||||
|---|---|---|---|---|---|---|---|
| Time of MI, days | 36 ± 14 | 512 ± 320 | — | ||||
| Cardiac function | |||||||
| LVEF, % | 65.9 ± 6.1 | 68.8 ± 8.8 | 70.4 ± 10.0 | ||||
| Type of treatment, | |||||||
| Chemical reperfusion | 1 (12.5) | 1 (8.3) | — | ||||
| Mechanical reperfusion | 6 (75.0) | 10 (83.4) | — | ||||
| Only standard medication | 1 (12.5) | 1 (8.3) | 9 (100) | ||||
| Number of vessels with stenosis, | Pre ( | Post ( | Pre ( | Post ( | |||
| Without stenosis | 1 (12.5) | 5 (62.5) | 0 | 5 (41.7) | 0 | ||
| One vessel | 0 | 2 (25.0) | 5 (41.7) | 3 (25.0) | 7 (77.8) | ||
| Two vessels or more | 7 (87.5) | 1 (12.5) | 7 (58.3) | 4 (33.3) | 2 (22.2) | ||
| Location of stenosis, | Pre ( | Post ( | Pre ( | Post ( | |||
| Anterior descending artery | 7 (100) | 2 (66.7) | 7 (58.3) | 0 | 8 (88.9) | ||
| Left circumflex artery | 4 (57.1) | 2 (66.7) | 8 (66.7) | 6 (85.7) | 1 (11.1) | ||
| Right coronary artery | 4 (57.1) | 0 | 5 (41.7) | 3 (42.8) | 2 (22.2) | ||
| Diagonal arteries | 1 (14.3) | 1 (33.3) | 3 (25.0) | 3 (42.8) | 0 | ||
| Marginal arteries | 1 (14.3) | 0 | 2 (16.7) | 1 (12.5) | 0 | ||
Data are presented as mean ± SD or absolute value (percentage) of occurrence. RMI, recent myocardial infarction group; LMI, late myocardial infarction group; CAD, stable coronary artery disease group; n, number of individuals; MI, myocardial infarction; LVEF, left ventricular ejection fraction; Pre, pretreatment; Post, posttreatment. Significant difference in relation to CAD. +Significant difference in relation to RMI. #Significant difference in relation to pretreatment (p < 0.05). The chi-square test and Fisher's exact test were used.
Resting pulmonary function, respiratory muscle strength, and CPET variables of all groups.
| RMI ( | LMI ( | CAD ( | CG ( | |
|---|---|---|---|---|
| Pulmonary function | ||||
| FVC, % predicted | 94.1 ± 9.6 | 98.8 ± 12.5 | 98.1 ± 10.1 | 101.9 ± 9.7 |
| FEV1, % predicted | 97.5 ± 13.4 | 96.8 ± 11.5 | 101.8 ± 6.4 | 100.9 ± 6.0 |
| FEV1/FVC | 0.83 ± 0.05 | 0.79 ± 0.06 | 0.80 ± 0.05 | 0.78 ± 0.03 |
| MVV, L/min | 145.5 ± 27.6 | 145.8 ± 25.1 | 142.4 ± 17.7 | 177.5 ± 30.4 |
| Respiratory muscle strength | ||||
| MIP, cmH2O | 96.0 ± 27.2 | 98.1 ± 14.1 | 97.1 ± 10.3 | 95.5 ± 21.6 |
| MIP, % predicted | 114.9 ± 5.4 | 111.6 ± 5.4 | 110.5 ± 5.8 | 113.8 ± 6.3 |
| MEP, cmH2O | 119.1 ± 31.7 | 131.4 ± 18.1 | 136.4 ± 19.6 | 139.7 ± 30.9 |
| MEP, % predicted | 121 ± 5.5 | 124.2 ± 4.4 | 120.4 ± 6.7 | 123.3 ± 6.4 |
|
| ||||
| VAT | ||||
| VO2, mL·kg−1·min−1 | 13.5 ± 2.6 | 15.6 ± 4.9 | 18.9 ± 4.2 | 18.6 ± 3.9 |
| RER | 0.87 ± 0.05 | 0.90 ± 0.04 | 0.87 ± 0.09 | 0.90 ± 0.04 |
| Peak | ||||
| Speed, km/h | 5.9 ± 0.4 | 6.2 ± 0.5 | 6.4 ± 0.3 | 6.7 ± 0.3 |
| Inclination, % | 12.7 ± 4.7 | 14 ± 5.2 | 12.3 ± 4.8 | 17.2 ± 3.6 |
| VO2, mL·min−1 | 1775 ± 383 | 1934 ± 409 | 1998 ± 461 | 2337 ± 543 |
| VO2, mL·kg−1·min−1 | 23.2 ± 6.2 | 23.7 ± 5.6 | 25.4 ± 4.9 | 30.7 ± 6.0 |
| VCO2, mL·min−1 | 2098 ± 423 | 2108 ± 504 | 2168 ± 412 | 2624 ± 597 |
| VE/VVM | 0.46 ± 0.08 | 0.44 ± 0.08 | 0.45 ± 0.17 | 0.45 ± 0.16 |
| RER | 1.18 ± 0.07 | 1.09 ± 0.09 | 1.10 ± 0.11 | 1.10 ± 0.05 |
| HR, bpm | 127 ± 20 | 143 ± 32 | 143 ± 17 | 165 ± 25 |
| VE/VCO2 slope | 32.4 ± 6.9 | 30.6 ± 3.9 | 26.6 ± 4.0 | 29.9 ± 4.3 |
Data are presented as mean ± SD. CPET, cardiopulmonary exercise testing; RMI, recent myocardial infarction group; LMI, late myocardial infarction group; CAD, stable coronary artery disease group; CG, control group; n, number of individuals; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; MVV, maximal voluntary ventilation; MIP, maximal inspiratory pressure; ME, maximal expiratory pressure; VAT, ventilatory anaerobic threshold; VO2, oxygen uptake; RER, respiratory exchange ratio; VCO2, carbon dioxide production; VE, minute ventilation; HR, heart rate; VE/VCO2 slope, ventilatory efficiency. Significant difference in relation to CG; +Significant difference in relation to CAD (p < 0.05). One-way ANOVA (Tukey post hoc) was used.
Constant workload exercise test variables (moderate and high intensity) of groups.
| RMI ( | LMI ( | CAD ( | CG ( | |||||
|---|---|---|---|---|---|---|---|---|
| Moderate | High | Moderate | High | Moderate | High | Moderate | High | |
| Speed, km/h | 5.2 ± 0.8 | 5.8 ± 0.4 | 6.0 ± 0.6 | 6.2 ± 0.5 | 6.2 ± 0.4 | 6.4 ± 0.3 | 6.4 ± 0.4 | 6.7 ± 0.3# |
| Inclination, % | 0.1 ± 0.2 | 7.6 ± 2.7# | 0.5 ± 0.9 | 10.1 ± 3.6# | 0.9 ± 2.1 | 8.8 ± 5.2# | 0.8 ± 1.7 | 11.1 ± 3.7# |
| VE, L.min−1 | 30.4 ± 5.4 | 54.1 ± 10.1# | 38.3 ± 11.1 | 63.1 ± 19.9# | 39.6 ± 9.5 | 65.8 ± 14.3# | 36.6 ± 4.4 | 63.9 ± 12.2# |
| VO2, mL·kg−1·min−1 | 13.4 ± 2+ | 20.2 ± 3.3# | 14 ± 3 | 22.3 ± 5# | 18.3 ± 4.5 | 24.4 ± 5.6# | 17.3 ± 3.1 | 28.6 ± 4.6# |
| PETCO2 (mL·kg−1·min−1) | 38.4 ± 2.6 | 37.5 ± 5.3 | 38.5 ± 1.4 | 36.7 ± 4.6 | 44.1 ± 5.6 | 38.1 ± 4.7# | 42.1 ± 2.2 | 38.7 ± 2.9# |
| VE/VCO2 | 30.1 ± 0.8 | 33.2 ± 4.6 | 31.0 ± 2.9 | 34.2 ± 5.0 | 27.6 ± 1.9 | 29.7 ± 4.4 | 27.3 ± 1.8 | 30.2 ± 2.6# |
| HR, bpm | 90 ± 9 | 112 ± 13 | 101 ± 16 | 127 ± 19# | 115 ± 21 | 147 ± 18# | 106 ± 14 | 139 ± 13# |
| IC, L | 3.5 ± 0.5 | 3.6 ± 0.5 | 3.2 ± 0.5 | 3.3 ± 0.7 | 3.3 ± 0.2 | 3.3 ± 0.4 | 3.3 ± 0.7 | 3.3 ± 0.6 |
Data are presented as mean ± SD. RMI, recent myocardial infarction group; LMI, late myocardial infarction group; CAD, stable coronary artery disease group; CG, control group; VE, minute ventilation; VO2, oxygen uptake; PETCO2, partial pressure of end-tidal carbon dioxide; VCO2, carbon dioxide production; HR, heart rate; IC, inspiratory capacity. Significant difference in relation to CG in the same situation. +Significant difference in relation to CAD in the same situation; #Significant difference in relation to moderate intensity (p < 0.05). Two-way ANOVA (Tukey post hoc) was used.
Figure 2Degree of expiratory flow limitation at moderate and high intensity exercise. Data are presented as median ± (25%–75% and minimum–maximum). EFL, expiratory flow limitation; VT, tidal volume; RMI, recent myocardial infarction group; LMI, late myocardial infarction group; CAD, stable coronary artery disease group; CG, control group. Difference in relation to CG in the same intensity. #Difference in relation to moderate intensity exercise (p < 0.05). The Kruskal–Wallis (Dunn post hoc) and Wilcoxon tests were used.
Figure 3Expiratory reserve volume (a) and inspiratory reserve volume (b) at moderate and high intensity exercise. Data are presented as mean ± SD. EVR, expiratory volume reserve; IVR, inspiratory volume reserve; RMI, recent myocardial infarction group; LMI, late myocardial infarction group; CAD, stable coronary artery disease group; CG, control group. Difference in relation to CG in the same intensity. #Difference in relation to moderate intensity exercise (p < 0.05). Two-way ANOVA (Tukey post hoc) was used.